Duloxetine Hydrochloride (HCI) — Competitive Intelligence Brief

Duloxetine Hydrochloride (HCI) (Duloxetine Hydrochloride (HCI)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Serotonin-norepinephrine reuptake inhibitor (SNRI). Area: Psychiatry, Neurology, Pain Management.

phase 3 Serotonin-norepinephrine reuptake inhibitor (SNRI) Serotonin transporter (SERT); Norepinephrine transporter (NET) Psychiatry, Neurology, Pain Management Small molecule

Target snapshot

Duloxetine Hydrochloride (HCI) (Duloxetine Hydrochloride (HCI)) — Eli Lilly and Company. Duloxetine inhibits the reuptake of serotonin and norepinephrine in the central nervous system, increasing their availability at synaptic sites.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Duloxetine Hydrochloride (HCI) TARGET	Duloxetine Hydrochloride (HCI)	Eli Lilly and Company	phase 3	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin transporter (SERT); Norepinephrine transporter (NET)
Pristiq	Desvenlafaxine Succinate	Pfizer	marketed	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin and norepinephrine reuptake	2008-01-01
Effexor	Venlafaxine Hydrochloride	Pfizer	marketed	Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)	Serotonin and norepinephrine reuptake transporters	1993-01-01
VenlafaxineXR	VenlafaxineXR	National Institute of Mental Health (NIMH)	marketed	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin transporter (SERT); Norepinephrine transporter (NET)
venlafaxine (Effexor)	venlafaxine (Effexor)	National Institute of Mental Health (NIMH)	marketed	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin transporter (SERT), norepinephrine transporter (NET), dopamine transporter (DAT, weak)
Venlafaxine XR	Venlafaxine XR	Ministry of Health & Welfare, Korea	marketed	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin transporter (SERT); Norepinephrine transporter (NET)
Drug treatment with Cymbalta	Drug treatment with Cymbalta	Jefferson Clinic, P.C.	marketed	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin and norepinephrine transporters

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Serotonin-norepinephrine reuptake inhibitor (SNRI) class)

1. Pfizer · 3 drugs in this class
2. Wyeth is now a wholly owned subsidiary of Pfizer · 3 drugs in this class
3. National Institute of Mental Health (NIMH) · 2 drugs in this class
4. Zhejiang Huahai Pharmaceutical Co., Ltd. · 2 drugs in this class
5. Eli Lilly and Company · 2 drugs in this class
6. New York State Psychiatric Institute · 1 drug in this class
7. North Dakota State University · 1 drug in this class
8. Ministry of Health & Welfare, Korea · 1 drug in this class
9. Purdue Pharma, Canada · 1 drug in this class
10. Shanghai Mental Health Center · 1 drug in this class